Abzena, a bioconjugate and complex biologics CDMO, has entered a partnership with ProteoNic Biosciences BV to license their protein expression technology, 2G UNic. This state-of-the-art vector technology is designed to significantly improve the production of high-yielding CHO cell lines for Abzena’s customers.   Under the agreement, Abzena gains worldwide, non-exclusive commercial rights for the application of ProteoNic’s 2G UNic vector technology in the development of high-yielding CHO cell l...